RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA : vimarsana.com

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that RHB-107 (upamostat)3 has been accepted for inclusion in the Austere environments Consortium for Enhanced Sepsis Outcomes' (ACESO) U.S. Government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment to be conducted in the U.S., Thailand, Ivory Coast and South Africa. The Company also announced that the Phase 2 study, predominantly funde

Related Keywords

China , United Kingdom , Macao , Macau General , Macau , United States , Taiwan , Hong Kong , Adi Frish , Redhill Biopharma , Nasdaq , Germany Heidelberg Pharmaceuticals , Program Executive Office For Chemical , Exchange Commission , Company Expanded Access Program , Department Of The Navy , Corporate Business Development , National Institutes Of Health Radiation , Department Of The Army , Redhill Biopharma Ltd , Nuclear Defense , Nuclear Countermeasures Program For Acute Radiation Syndrome , Consortium For Enhanced Sepsis Outcomes , Company Annual Report On Form , Department Of Defense , Military Medicine , Gilead Raday , Chief Operating Officer , National Institutes , Health Radiation , Nuclear Countermeasures Program , Acute Radiation Syndrome , Heidelberg Pharmaceuticals , Joint Program Executive Office , Joint Force , Enhanced Sepsis Outcomes , Hill Biopharma , Private Securities Litigation Reform Act , Expanded Access Program , Annual Report , Hjf , Cceso , Peo Cbrnd , Redhill Biopharma Ltd , Oint Program Executive Office For Chemical , Iological , Hb 107 , Henrym Jackson Foundation , Edhill , Investigational Products , Hase 2 Study ,